reports
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registratio...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for submission to multiple regulatory agencies. ECLIPSE 3, a Phase 2b trial, is designed to provide importa...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising programs in infectious diseases and oncology,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “As we enter 2025, we are poised for significant advancement with the initiation of ou...
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care C...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts. A live webcast of the fireside chat will be made available under in the Investors section of the and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering...
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarte...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be provided via a press release after market close and will be accessible on the in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the of...
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in On...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation continues, and early clinical response signals observed in heavily pretreated participants. These init...
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on pow...
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EM...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new at AASLD The Liver Meeting® in San Diego, U.S. Vir Biotechnology’s Phase 3 ECLIPSE registrational program eval...
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN™ platform on January 8, 2025, at 5:00 a.m. PT / 8:00 a.m. ET. A live webcast will be available on and will be archived on for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biophar...
Vir Biotechnology to Participate in the 7th Annual Evercore ISI Health...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage bi...
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical T...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta (CHD). The most-advanced and potential first-of-its-kind investigational human monoclonal antibody and siRNA combination dosed monthly achieved 100% virologic response and rapid hepatitis delta virus (HDV) RNA suppression. HDV RNA below the lower limit of quantification (< LLOQ), target not detected (TND), the best measure that the virus is cleared fro...
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting® in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference cal...
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobe...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Pro...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. “This quarter was transformational for Vir. We have bolstered our clinical pipeline with three potential best-in-class dual-masked T-cell engagers in oncology, and have sharpened our focus within infectious diseases to the areas where we believe we can make the most significant impact for patients. We are also thrilled to welcome Jason O’Byrne as our new CFO. Jason brings a wealth of financial leadership experie...
Vir Biotechnology to Provide Business Update and Report Third Quarter ...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at . Participants may access the conference call via webcast on the Eve...
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta a...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of tobevibart, an investigational monoclonal antibody (mAb), and elebsiran, an investigational small interfering ribonucleic acid (siRNA) for the potential treatment of chronic hepatitis delta. These data will be presented in an oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, in San Diego, CA, November 15-19, 2024. Vir will also presen...
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Vir...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage bioph...
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne will join the Vir Executive Management Team and report directly to the company’s Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O’Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and...
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agr...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage masked T-cell engagers (TCEs) with potential applications in a range of cancers and exclusive use of the proprietary PRO-XTENTM masking platform for oncology and infectious disease. Key employees from Sanofi with extensi...
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Glo...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage bioph...
Vir Biotechnology Reports Second Quarter 2024 Financial Results and An...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. “The positive preliminary SOLSTICE Phase 2 study together with the recent FDA IND clearance and Fast Track designation for tobevibart and elebsiran for the treatment of chronic hepatitis delta infection highlight the encouraging momentum we’re building towards addressing the substantial unmet medical need for patients affected by this life-threatening disease,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chie...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.